risks of glp 1 agonists The expanding role GLP-1 receptor agonists: a narrative review of current evidence and future directions Peptide/GLP-1 Complications: 11 Hidden Risks

The primary endpoint, the between-group change in left ventricular mass, demonstrated that tirzepatide significantly reduced left ventricular mass and paracardiac adipose tissue compared to placebo, with reductions in weight loss

Lisdexamfetamine is an FDA approved for attention deficit hyperactivity disorder (ADHD) in 6 years and older, and for binge eating disorder in patients 18 years and older and is used off label in younger children with obesity and MASLD with ADHD, binge eating behavior, or impulsive mindless eating

Eli Lilly is expected to release Phase 3 results on the drug in late 2025 or early 2026

(United States)

E.CarraroR.FinerN.HartvigH.LindegaardM